Advert - Daiichi Sankyo – Case AUTH/3612/2/22

• Date posted
  16 June 2023
• Sanction
  Advertisement,
• Case number/s
  AUTH/3612/2/22 - Complainant v Daiichi Sankyo

For failing to make the contraindication with simvastatin >40mg immediately apparent when presenting Nilemdo (bempedoic acid) and Nustendi (bempedoic acid and ezetimibe) indications which referred to their therapeutic use in combination with a statin; and for failing to display prescribing information for adequate time for each medicine during a live symposium, Daiichi Sankyo was ruled in breach of the following Clauses of the 2021 Code:

Clause 2 - Bringing discredit upon, and reducing confidence in, the
pharmaceutical industry
Clause 5.1 - Failing to maintain high standards
Clause 12.5 - Failing to display prescribing information for sufficient duration so that it is easily readable